| CAS NO: | 222716-34-9 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 420.52 |
|---|---|
| Formula | C24H24N2O3S |
| CAS No. | 222716-34-9 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 10 mM in DMSO |
| Water: <1 mg/mL | |
| Ethanol: <1 mg/mL | |
| SMILES | O=C1C(C2=NC3=CC=CC=C3S2)=COC4=C(CN5CCCCC5)C(O)=C(CC)C=C14 |
| Synonyms | SKP2 E3 Ligase Inhibitor III; SZL-P1-41; SZL P1 41; SZLP141; |
| In Vitro | In vitro activity: SZL P1-41 also phenocopies the effects observed upon genetic Skp2 deficiency, such as suppressing survival, Akt-mediated glycolysis as well as triggering p53-independent cellular senescence. SZL P1-41 prevent Skp2-Skp1 interactions and Skp2 SCF E3 ligase activity. The reference concentration is 5 uM. SZL P1-41 restricts cancer cell survival through triggering p53-independent cellular senescence and inhibiting aerobic glycolysis. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | SZL P1-41 exhibits potent anti-tumor activities in multiple animal models and cooperates with chemotherapeutic agents to reduce cancer cell survival. |
| Animal model | |
| Formulation & Dosage | |
| References | Cell. 2013 Aug 1;154(3):556-68. |
m.cnreagent.com